PATENT CLAIM ANALYSIS

Application Number: 16184748
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["435", "006100"]

Abstract:
A gene expression signature identifies stage II colon and/or Stage III cancer patients who will receive benefit from oxaliplatin. Oxaliplatin has been shown to lengthen the survival of colon cancer patients, when it is combined with 5-fluorouracil plus leucovorin (FULV) in NSABP clinical trial C-07. Gene expression signatures are used first to classify tumors with regard to their respective subtypes, enterocyte, TA, goblet, inflammatory and stem-like and detection of expression of the enterocyte subtype directs treatment of the patient with oxaliplatin.

Claim (Index 5):
A method for treating colon cancer in a patient with Stage II or Stage III colon cancer comprising:\n a) obtaining a colon cancer tumor tissue sample from a patient with Stage II or Stage III colon cancer, b) isolating RNA or producing a lysate from the colon cancer tumor tissue sample, c) contacting said RNA or said lysate with a plurality of sequence specific probes capable of determining the level of expression of a panel of 72 genes, wherein the panel of 72 genes are AKAP12, ANKRD44, BGN, BHLHE41, BMP7, C8orf84, CAB39L, CDKN2B, CKMT2, COL11A1, COMP, CPE, CSGALNACT1, CXCL10, CXCL11, CXCL13, CXCL2, CXCL9, CYP1B1, DAPK1, DCBLD2, DPEP1, EPB41L4B, ERAP2, F5, FAP, FGL2, FN1, FNDC1, GBP1, GBP4, GPX3, GRM8, GZMB, HGD, HOXA13, HSD17B2, ID4, IDO1, IL8, INHBA, MFAP5, MGP, MMP11, MMP28, NFIB, OAS2, PAPPA, PIGR, PLA2G12B, POU2AF1, PRAP1, PROM2, PSMB9, PTPRC, ROBO1, SDC2, SELL, SERPINE1, SFRP2, SGK2, SLC4A4, SPARC, SPP1, SSPN, STC1, TACSTD2, TGFBR3, TM4SF1, TYMS, VCAN, and VNN1, d) measuring the gene expression level of the panel of 72 genes and obtaining a gene expression signature for said colon cancer tumor tissue from the gene expression level of said genes in c), e) responsive to the gene expression signature, identifying said colon cancer tumor tissue as being a subtype responsive to oxaliplatin, and f) administering oxaliplatin to said patient with Stage II or Stage III colon cancer.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 98.0
- Lexical Diversity: 1.33824
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14738757', '14346693', '14209266', '13992020', '13401780']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.4963643447147342
- 35 USC 102 Novelty (BERT): 0.6758246548862779
- Combined Prediction Score: 0.5143103757318885
- Mean Citation Score: 303.936754
- Max Citation Score: 671.14923
- Similarity Product: 652.6044358133519

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test